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Abstract
Background: The extent of lymphadenectomy during laparoscopic right colectomy can affect the oncological
outcome and the safety of surgery. The principle of complete mesocolic excision (CME) has been gradually
accepted and increasingly applied by colorectal surgeons. The aim of this study is to investigate whether extended
lymphadenectomy (CME) in laparoscopic colectomy could improve the oncological outcomes of patients with
right-sided colon cancers, compared with D2 lymphadenectomy.
Methods/design: The Radical Extent of lympadenectomy: D2 dissection versus complete mesocolic excision of
LAparoscopic Right Colectomy for right-sided colon cancer (RELARC) study is a prospective, multicenter, randomized
controlled trial in which 1072 eligible patients with right-sided colon cancers will be randomly assigned to the CME
group or the D2 dissection group during laparoscopic right colectomy. Inclusion criteria are locally advanced colon
cancers situated from the cecum to the right third of the transverse colon and clinically staged as T2-4aN0M0 or
TanyN +M0. The primary endpoint of this trial is 3-year disease-free survival. Secondary endpoints include 3-year overall
survival, postoperative complication rates, perioperative mortality rates, and rates of positive central lymph nodes
(the station 3 nodes).
Discussion: The RELARC trial is a prospective, multicenter, randomized controlled trial that will provide evidence on
the optimal extent of lymphadenectomy during laparoscopic right colectomy in terms of better oncological outcome
and operation safety.
Trial registration: ClinicalTrials.gov: NCT02619942. Registered on 29 November 2015.
Keywords: Colon cancer, Laparoscopic right colectomy, Complete mesocolic excision, Oncological outcome
* Correspondence: xiaoy@pumch.cn
1Department of General Surgery, Peking Union Medical College Hospital,
Chinese Academy of Medical Sciences and Peking Union Medical College, #1
Shuai Fu Yuan Street, Beijing 100730, People’s Republic of China
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lu et al. Trials  (2016) 17:582 
DOI 10.1186/s13063-016-1710-9
Background
Colorectal cancer is one of the most common malignant
diseases worldwide. In China, both the incidence and
mortality of the disease have been increasing during the
past decades, due to the aging population, changing life-
styles, and eating habits. In 2011, an estimated incidence
of 23.03/10 million was reported in China, accounting
for the fourth most common type of malignant tumor.
With a mortality rate of approximately 11.11/10 million,
colorectal cancer was the fifth leading cause of cancer-
related death in China [1].
Since Hohenberger first proposed the concept of
complete mesocolic excision (CME) in 2009, the principle
of CME has been gradually accepted and increasingly ap-
plied by colorectal surgeons as an optimal colectomy ap-
proach for colon cancer [2, 3]. According to this principle,
the extent of lymphadenectomy of the radical right colec-
tomy is similar to that of D3 lymph node dissection, which
was advocated by the Japanese Society for Cancer of the
Colon and Rectum (JSCCR) in the twentieth century [4]. In
CME, the central vascular ligation (CVL) enables more rad-
ical removal of the metastatic lymph nodes. The resection
in the mesocolic plane guarantees radical excision of the
tumor and the potential vascular or neural infiltration in
the whole regional draining area, which theoretically would
improve the oncological outcome in comparison with the
conventional right colectomy with D2 lymphadenectomy.
However, compared to D2 dissection, laparoscopic CME or
D3 dissection imposes a longer learning curve for the sur-
geons and a higher surgery-related risk for patients due to
the complicated surgical anatomy involved in the laparo-
scopic approach, especially the dissection in the vicinity of
the superior mesenteric vessels [5–8]. Neither the National
Comprehensive Cancer Network (NCCN) guidelines nor
the European Society for Medical Oncology (ESMO) guide-
lines have clearly defined the extent of lymphadenectomy
of the radical right colectomy [9]. D3 lymphadenectomy
was also advocated for locally advanced colorectal cancer
by the Chinese standard for diagnosis and treatment of
colorectal cancer, but CME was not mentioned [10]. In
addition, all the results indicating improved survival rate of
CME surgery compared to traditional D2 dissection were
drawn from retrospective studies [2, 11–15]. Therefore, a
well-designed prospective clinical trial is crucial to investi-
gate the optimal extent of lymphadenectomy of laparo-
scopic right colectomy for right-sided colon cancer. The
study protocol has been written in accordance with the
Standard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) checklist (see Additional file 1).
Methods/design
Study design
This study is a superiority trial. The main objective is to
investigate whether extended lymphadenectomy (CME) in
laparoscopic colectomy could improve the oncological out-
comes of patients with right-sided colon cancer, compared
to laparoscopic colectomy with D2 lymphadenectomy.
The study design is a prospective, multicenter, ran-
domized, two-arm, parallel-group, single-blind clinical
trial. The enrolled participants with right-sided colon
cancers, including cancers situated from the cecum to
the right third of the transverse colon, will be divided
into two groups: the laparoscopic CME group (the inter-
vention group) and the laparoscopic colectomy with D2
dissection group (the control group).
According to the final pathological results of surgical
specimens, patients with stage III colon cancer or
stage II disease with unfavorable histological features
will be required to undergo adjuvant chemotherapy for 6
months. The oxaliplatin-based combination regimen will
be recommended.
All the patients will be followed up regularly for at
least 5 years, according to the follow-up protocol recom-
mended by the NCCN guidelines. All patients are required
to undergo postoperative examinations every 4 months for
the first 2 years and every 6 months thereafter until 5 years
after the surgery. Signs of suspected disease relapse includ-
ing local recurrence (LR) or distant metastasis (DM) will be
closely observed and monitored. The schedule of this trial
is shown in Table 1.
Our study is expected to last 7 years, including 4 years
for recruiting patients and 3 years for follow-up.
Endpoints
The primary endpoint of this trial is 3-year disease-free
survival (DFS). Secondary endpoints include 3-year overall
survival (OS), postoperative complication rates, periopera-
tive mortality rates, and rates of positive central lymph
nodes (the station 3 nodes).
Definition of some postoperative complications
Anastomotic leak, postoperative diarrhea, and chylous
ascites are possible postoperative complications. Anasto-
motic leak is described as the presence of luminal
contents through a drain or wound site or an abscess
cavity causing inflammation (i.e., fever, leukocytosis, or
fecal discharge). An anastomotic leak may be detected
using radiologic studies, but it must exhibit clinical signs
of leakage to be considered a clinical leak.
Postoperative diarrhea shows abnormal feces, such as
loose stool, watery stool, mucous stool, or bloody puru-
lent stool three times or more a day within 2 weeks after
the operation.
Chylous ascites is defined as the presence of non-
infectious milky or creamy peritoneal fluid in the drain-
age tubes with a volume of ≥200 mL/day and a positive
chyle test.
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Participating centers and investigators
Seventeen tertiary university hospitals will enroll patients
in China. The surgeons who participate in the study
should have experience of more than 100 cases of lap-
aroscopic colorectal surgery per year for 2 consecutive
years and the ability to complete the skilled laparoscopic
CME procedure. Every investigator should provide oper-
ation videos of CME and D2 procedures within the past
3 months; these videos will be reviewed by the review
committee.
Ethical considerations
This trial protocol is approved by the Ethics Committee
of Peking Union Medical College Hospital (reviewed in
2015 as ZS-851) and has been registered at Clinical-
Trials.gov (identifier NCT02619942). All of the eligible
participants and their legal surrogates will be fully in-
formed of the potential risks and benefits of the inter-
ventions in each group. Only patients who are willing
to provide written informed consent can be enrolled in
the trial.
Study subjects
The study subjects are patients with locally advanced
right-sided colon cancers, including carcinomas located
at the cecum, the ascending colon, the hepatic flexure,
and the right third of the transverse colon.
The inclusion criteria are as follows:
1. Age 18–75 years old
2. Pathologically confirmed adenocarcinoma of right
side of colon
3. Localization of the tumor ranging from the cecum
to the right third of the transverse colon
4. Tumors clinically staged as T2-4aN0M0 or TanyN +
M0, according to imaging studies including enhanced
computed tomography (CT) scan, magnetic resonance
imaging (MRI), etc.
5. American Society of Anesthesiologists (ASA) score
of I, II, or III.
The exclusion criteria are as follows:
1. Synchronous or metachronous multiple primary
colorectal cancer
2. Preoperative imaging examination shows
enlargement of the central lymph nodes, which
mandates a D3 lymphadenectomy
3. Preoperative imaging examination shows that the
tumor involves the adjacent organs, requiring
combined multiple organ resections, or radical
excision (R0 resection) is not possible
4. History of any other malignant tumor in past 5
years, except for cervical carcinoma in situ that has
been cured, basal cell carcinoma, or squamous cell
carcinoma of skin
5. Patients who need an emergency operation
6. Patients who are not suitable to undergo
laparoscopic surgery (due to, e.g., extensive adhesion
caused by prior abdominal surgery, inability to
endure artificial pneumoperitoneum, etc.).
Exit criteria include:
1. Patients with distant metastasis that is discovered
during surgical exploration or confirmed by the
postoperative pathologic examination
2. Combined organ resection during the surgery
3. Fusion of central lymph nodes at the mesenteric
root discovered during the operation.
This study is scheduled to enroll consecutive patients
in 17 tertiary medical centers in China. Patients enrolled
in this clinical research will be guaranteed high-quality
surgical procedures and standard medical treatment as
well as convenient long-term follow-up.
Randomization and blinding
Patients enrolled in this study will be randomly assigned
into either the study group or the control group. The
random numbers are generated using Statistical Analysis
System (SAS) software to ensure that patients are ran-
domly divided into two groups with an allocation ratio
of 1:1. A central randomization system will be employed,
and all the researchers must register at the website of
the research system. When a researcher has chosen a
certain patient, he/she should log on to the webpage and
upload the basic information on the patient before ac-
quiring the random grouping schemes.
All the patients are blinded to the surgical approach
that they are going to receive, and will be required to
sign the informed consent before being enrolled in the
study. Obviously, it is impossible to blind the surgeons
who will perform the surgeries. However, all the surgeon
researchers will be required to limit potential co-
interventions as much as possible. In addition, the result
assessment will be made by independent researchers
who are blinded to the surgical procedures.
Preoperative evaluation
A diagnosis of colon cancer must be pathologically con-
firmed before the surgery, using the biopsy specimen ac-
quired from the colonoscopy. An enhanced CT scan of
the abdominal and pelvic cavity is performed to localize
the lesion. A CT colonography (virtual colonoscopy) or
double-contrast barium enema can be performed when
necessary.
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An enhanced CT scan of the abdomen and pelvis can
also provide information about the depth of tumor infil-
tration, the status of the regional lymph node metastasis,
and the involvement of adjacent organs. A whole body
enhanced CT scan can also demonstrate distant meta-
static disease, such as liver, lung, and even peritoneum
metastases. If necessary, other examinations including
abdominopelvic MRI, contrast-enhanced ultrasound of
the liver, endoscopic ultrasound, whole body bone scan,
and positron emission tomography (PET)-CT can be
used to facilitate the preoperative evaluation.
Surgery
Surgical procedures for the two groups require sharp
dissection strictly following the anatomical planes (also
called embryonic planes) [2], including both the anterior
and posterior aspects of the mesocolon, and separate the
Toldt’s fascia from the retroperitoneum with an intact
package of the tumor and its main lymphatic drainage
(see Additional file 2). Complete mobilization of the
mesocolon and complete removal of the vessels and lymph
nodes inside will be achieved. The main differences be-
tween the two groups include the extent of lymphadenec-
tomy (D2 versus D3); and whether or not to dissect the
lymphoadipose tissues at the root of the mesocolon, which
cover the anterior surface of the superior mesenteric artery
(SMA) and vein (SMV), and the tissues surrounding the
root of the middle colic artery.
There is no difference between the two groups in the
extent of longitudinal resection. All procedures are basic-
ally a right hemicolectomy. The ileum is divided at 5–10
cm of the cecum. For cancer of the cecum and ascending
colon, only the right branches of the middle colic vessels
are divided centrally, and the colon is divided right at the
level of the middle colic vessels. Cancer of the hepatic
flexure and the right third of the transverse colon requires
true central ligation of the middle colic artery and vein
with resection of the transverse colon in the proximity of
the splenic flexure, as well as a central tie of the right gas-
troepiploic artery and vein.
For D2 lymphadenectomy
The D2 lymphadenectomy is performed to remove the
whole anterior and posterior aspects of the mesocolon
and the lymphoadipose tissues covering the anterior sur-
face of the pancreatic head and neck, which represent
the mesenteric roots of the ascending colon and the
right third of the transverse colon respectively (Fig. 1).
This procedure is required along the anatomical planes
(embryonic planes) and is followed by ligation of the co-
lonic supplying vessels right of the SMV and cleaning up
of the surrounding lymphoadipose tissue (Fig. 2).
For CME procedure
In addition to the dissecting area described in the D2
procedure, the CME procedure cleans up the lymphoa-
dipose tissue on the surface of the SMA and SMV. This
requires further exposure and skeletalization of the right
and anterior sides of the SMV, including the surgical
trunk. This exposure should remove the lymphoadipose
tissues instead of the connective tissues covering the
SMA, to expose its outline (Fig. 3). Then, it is followed
by the ligation of the supplying vessels (both artery and
vein) at their origins; the results are shown in Fig. 4.
Postoperative evaluation
At the end of the surgery, the surgeon must take photos
of the specimens and upload them to the central web-
site. Both the anterior and posterior sides of the speci-
mens are taken alongside a metric scale for calibration.
The mesentery is laid out flat without external tension,
indicating the sites of the tumor and vascular ties. The
diameter of the tumor, the distance between the prox-
imal and distal cutting edge to the tumor, and the dis-
tance between the most distant free mesocolon and the
Fig. 1 D2 lymphadenectomy requires dissecting the supplying
vessels right of the superior mesenteric vein (SMV) and keeping the
covering lymphoadipose tissue of the SMV intact. a Right colic vein.
b Pancreas neck. c Henle’s trunk. d Inferior pancreaticoduodenal
vein. e Pancreas head. f Duodenum. g Undissected SMV
Fig. 2 During D2 lymphadenectomy, the supplying vessels are
ligated right of the SMV
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tumor are also precisely measured. The area of mesen-
tery resected will be calculated after the operation by the
parameters collected in the operation room.
The quality of the surgical specimens is graded from
the integrity of the mesocolon by an independent review
committee using a method described previously [3]. The
grading of surgical specimens is classified into three groups:
good (intact anterior and posterior fascia of mesocolon, in-
tact lymphoadipose tissue from the surface of SMV in
CME procedure), moderate (defects of mesocolic fascia that
expose the mesocolic fat, but the incisions do not reach
down to the muscularis propria), or poor (significant de-
fects of mesocolon or disruptions extending down onto the
muscularis propria). Any discrepancies of the grades will be
discussed before a final grade is agreed on.
Postoperative adjuvant therapy
The postoperative adjuvant chemotherapy is determined
by the pathological results. For patients with stage III
disease and patients of stage II with unfavorable histo-
logical features, 6 months of adjuvant chemotherapy
using an oxaliplatin-based combination regimen is rec-
ommended. For patients of stage II without unfavorable
histological features, adjuvant chemotherapy is deter-
mined by the microsatellite instability (MSI) state. For
patients with microsatellite stability (MSS), single-agent
chemotherapy based on 5-fluorouracil (5-FU) is rec-
ommended. For patients with MSI, we suggest just ob-
servation and regular follow-ups.
Follow-up and data collection
The postoperative examination will be performed every
4 months in the first 2 years and every 6 months in the
following 3 years. Disease-free survival (DFS) is defined
as the time from randomization to the time of finding
the recurrence, metastasis, or death. It is calculated on a
monthly basis for the latest finding. Local recurrence is
defined as a recurrence of the tumor in the surgical re-
gion, with or without elevation of serum tumor markers,
and the mass of the anastomotic site must be confirmed
by a pathological biopsy. A distant metastasis is defined
as a metastasis that is discovered in the liver, lung, bone,
or other sites by CT, MRI, or radionuclide scanning, with
or without pathological examination. The postoperative
complications that are included in the statistics include
intra-abdominal hemorrhage, gastrointestinal bleeding,
anastomotic leakage, chylous fistula, surgical site infection,
including intra-abdominal infections and wound infection,
intestinal obstruction, postoperative diarrhea, pulmonary
infection, urinary tract infection, cardiovascular accident,
cerebral vascular accident, and thrombotic disease.
Sample size calculation
Previous retrospective studies reported that the 3-year
DFS for the D2 operation ranged from 66.7% to 82.1%;
the range was 77.4% to 89.1% for the CME operation
[10, 15]. We estimate that the 3-year DFS for D2 and
CME will be 72.0% and 80.0% respectively in this study.
We expect to detect a difference of 8% in 3-year DFS be-
tween the two groups. Thus, with a significance level of
5%, a two-sided test, and 80% power, 447 patients will be
required for each group. With a drop-out rate of 20%,
the required sample size is 1072 patients for both arms.
Statistical analysis
Continuous variables will be expressed as mean, standard
deviation, median, minimum, maximum, Q1, and Q3.
Categorical variables will be expressed as numbers and
percentages. The t test and Wilcoxon rank sum test will
be used to compare continuous variables, and chi-square
analysis/Fisher’s exact test will be used to compare cat-
egorical variables. Survival analysis will be conducted
using the Kaplan-Meier method and the log-rank test.
Fig. 3 The CME procedure requires cleaning the lymphoadipose
tissue on the surface of the SMA and ligating the supplying vessels
at their origins. a Right colic artery. b Superior mesenteric vein.
c Ileocecal artery and vein
Fig. 4 After complete removal of the ascending and transverse
mesocolon from the roots, the pancreatic head and neck are clearly
exposed during the CME procedure. a Pancreas neck. b Henle’s trunk.
c Ligated right colic artery. d Pancreas head. e Superior mesenteric
vein (surgical trunk). f Ligated ileocecal vessels. g Duodenum
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Statistical analysis will be carried out using SAS 9.2. All
statistical tests are two-sided tests, and a P value less than
or equal to 0.05 is considered as statistically significant.
Data and safety monitoring
An independent Data and Safety Monitoring Board
(DSMB) including senior colorectal surgeons, biostatisti-
cians, a research contractor, and an ethicist has been set
up. DSMB members will meet before the study and
every 6 months during the study. The DSMB will review
elements of the study, including adverse events (AEs),
drop-outs, and endpoints. If the interim results show a
huge difference between the two groups that is much
more than anticipated, the DSMB can stop the study
early for the safety and benefit of the patients.
Discussion
In the past 30 years, the development of surgery for
colorectal cancer has been unbalanced. The surgical pro-
cedure for colon cancer is relatively unchanged, but the
surgical treatment of rectal cancer has been constantly
evolving. Contributing factors to this situation include the
double-stapling technique, the principle of total mesorec-
tal excision (TME), the 2-cm distal margin, neoadjuvant
therapy, and other new technologies.
The transformation of traditional open surgery to min-
imally invasive surgery has become an inevitable trend.
Some high-level clinical studies have shown that laparo-
scopic surgery and open surgery did not have significant
differences in the long-term oncological outcomes or the
short-term effect for colorectal cancer [16–18]. The 2015
NCCN guidelines for colon cancer advocated laparoscopic
colectomy to experienced surgeons. The incidence of right
colon cancer accounts for more than 50% of colon cancer
occurrence. Right colectomy is relatively consistent, and
open right colectomy is even considered to be the entry
procedure for colorectal specialists. The anatomical layers
in laparoscopic right colectomy, however, are more com-
plicated compared to other parts of colon cancer surgery
by the laparoscopic approach, and vascular variation in
this region is common. Therefore, the difficulty of laparo-
scopic right colectomy is greater than that of the open
procedure [5]. Neither the NCCN nor the ESMO guide-
lines have clearly defined the extent of lymphadenectomy
for a radical right colectomy. Therefore, the key steps of
laparoscopic right colectomy are still controversial.
The concepts of D3 dissection and CME developed in
different eras and different countries. The concept of
CME historically originated from TME, which empha-
sized dissection along the embryologic plane and ligation
of the supplying vessels at their origins. The other differ-
ence between D3 dissection and CME is the longitudinal
resection (longitudinal margin of 10 cm versus right hemi-
colectomy), the latter technique bring a more extensive
longitudinal removal. In the present study, all procedures
require sharp dissection strictly following the embryologic
plane and are basically a right hemicolectomy, which is
different from D3 dissection. For cancer of the hepatic
flexure and right third of the transverse colon, more ex-
tensive resection of the transverse colon in the proximity
of the splenic flexure is recommended.
In the past 30 years, similar disputes or innovations
for gastrointestinal surgeries include the principle of
TME for rectal cancer, the extent of lymph node dissec-
tion for gastric cancer, and lateral lymph node dissection
for rectal cancer, etc. The principle of TME received
general approval immediately after it came out because
it did not increase the difficulty of the operation and
achieved less bleeding, although it was not confirmed by
randomized controlled studies. However, other issues,
including D2 or more extended lymphadenectomy for
advanced gastric cancer [19, 20] and the necessity of lateral
lymph node dissection for rectal cancer, were controversial
[21]. Eventually, some advanced studies of evidence-based
medicine settled the arguments and formed the current
guidelines. The concept of CME originated from TME, but
whether it can achieve the same acceptance as TME still
needs to be verified in practice.
Trial status
This trial was initiated in January 2016 and is currently
recruiting patients.
Additional files
Additional file 1: SPIRIT 2013 checklist. (DOCX 26 kb)
Additional file 2: Schematic diagram depicting complete mobilization
of mesocolon. The plane of dissection lies between Toldt’s fascia and the
retroperitoneum. (JPG 823 kb)
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